Dongsheng Yu

3.0k citations
60 papers · 2.3k indexed · 3 hit papers · h-index 20
Topics
RNA modifications and cancer (6 papers)Nanoplatforms for cancer theranostics (5 papers)Autophagy in Disease and Therapy (5 papers)

In The Last Decade

Dongsheng Yu

53 papers receiving 2.3k citations

Hit Papers

A strongly adhesive hemostatic hydrogel for the repair of...2017202620202023201920172022200400600

Peers

Dongsheng Yu
Comparison fields: 5 of 131
  • Molecular Biology 914
  • Surgery 500
  • Cancer Research 325
  • Biomaterials 308
  • Biomedical Engineering 301
Replace Dechun Geng with:
Dechun Geng China
Jiaxiang Bai China
Liliane Louedec France
Iwona Cicha Germany
Lin Cai China
Karen Fox-Talbot United States
Toshiaki Ishizuka Japan
Yu Song China
Jesse Li‐Ling China
Dongsheng Yu relative to Dechun Geng China Dechun Geng's profile →
Citations per field
00.5×1.5×
Dechun Geng · 1×
Citations per year

Countries citing papers authored by Dongsheng Yu

Since Specialization
Citations

This map shows the geographic impact of Dongsheng Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dongsheng Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dongsheng Yu more than expected).

Fields of papers citing papers by Dongsheng Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dongsheng Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dongsheng Yu. The network helps show where Dongsheng Yu may publish in the future.

Co-authorship network of co-authors of Dongsheng Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Dongsheng Yu. A scholar is included among the top collaborators of Dongsheng Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dongsheng Yu. Dongsheng Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 5
3 0
4 0
5 1
6 3
7 6
8 2
9 6
10 6
11 3
12 10
13 26
14 13
15 45
16 42
17 10
18 73
19 5
20 23

About Dongsheng Yu

Dongsheng Yu is a scholar working on Cancer Research, Immunology and Allergy and Molecular Biology, having authored 60 papers that have together received 2.3k indexed citations. Recurring topics across this work include RNA modifications and cancer (6 papers), Nanoplatforms for cancer theranostics (5 papers) and Autophagy in Disease and Therapy (5 papers). The work is most often cited by research in Rehabilitation (227 citations), Molecular Medicine (138 citations) and Hematology (264 citations). Dongsheng Yu has collaborated with scholars based in China, South Korea and Hong Kong. Frequent co-authors include Bao Sun, Hongwei Ouyang, Xiaohui Zou, Chunsheng Zhu, Zheng Zhou, Shufang Zhang, Xianzhu Zhang, Yiwei Zou, Yi Hong and Feifei Zhou. Their work appears in journals such as Angewandte Chemie International Edition, Nature Communications and Biomaterials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026